Cubist Systematic Strategies LLC Has $2.02 Million Position in Keros Therapeutics, Inc. $KROS

Key Points

• Cubist Systematic Strategies LLC significantly increased its investment in Keros Therapeutics, holding $2.02 million in shares after purchasing an additional 197,201 shares, representing a 16,297.6% increase in the first quarter.
• Multiple hedge funds have also made significant investments in Keros Therapeutics, with over 71.56% of the stock owned by institutional investors.
• Recent analyst reports have lowered the target prices for Keros Therapeutics, with a consensus rating of "Moderate Buy" and a target price dropping to $30.00, reflecting varying sentiments on the stock's performance.

Cubist Systematic Strategies LLC grew its holdings in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 16,297.6% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 198,411 shares of the company's stock after acquiring an additional 197,201 shares during the quarter. Cubist Systematic Strategies LLC owned 0.49% of Keros Therapeutics worth $2,022,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Two Sigma Investments LP grew its holdings in shares of Keros Therapeutics by 226.1% during the fourth quarter. Two Sigma Investments LP now owns 33,664 shares of the company's stock worth $533,000 after buying an additional 23,342 shares in the last quarter. BNP Paribas Financial Markets bought a new position in shares of Keros Therapeutics during the fourth quarter worth about $730,000. Jump Financial LLC bought a new position in shares of Keros Therapeutics during the first quarter worth about $1,058,000. Tejara Capital Ltd bought a new position in shares of Keros Therapeutics during the first quarter worth about $410,000. Finally, TFG Asset Management GP Ltd bought a new position in shares of Keros Therapeutics during the fourth quarter worth about $1,630,000. 71.56% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

KROS has been the subject of a number of research reports. Bank of America downgraded Keros Therapeutics from a "buy" rating to a "neutral" rating and decreased their price objective for the stock from $32.00 to $18.00 in a report on Tuesday, June 10th. Wedbush reissued a "neutral" rating and set a $15.00 price target on shares of Keros Therapeutics in a research report on Friday, May 30th. Finally, HC Wainwright reduced their price target on Keros Therapeutics from $25.00 to $20.00 and set a "buy" rating for the company in a research report on Friday, August 8th. Seven equities research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $30.00.

Keros Therapeutics Trading Down 0.6%

Shares of KROS traded down $0.10 during mid-day trading on Friday, reaching $15.66. The company's stock had a trading volume of 245,553 shares, compared to its average volume of 430,660. Keros Therapeutics, Inc. has a 1-year low of $9.12 and a 1-year high of $72.37. The stock has a market cap of $636.11 million, a P/E ratio of 50.52, a PEG ratio of 2.03 and a beta of 1.06. The business has a 50-day simple moving average of $14.62 and a two-hundred day simple moving average of $13.48.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($0.76) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.14) by $0.38. Keros Therapeutics had a return on equity of 2.96% and a net margin of 8.06%.The company had revenue of $0.02 million during the quarter, compared to analysts' expectations of $3.83 million. During the same period last year, the firm posted ($1.25) earnings per share. The business's revenue was up 49002.7% on a year-over-year basis. Research analysts anticipate that Keros Therapeutics, Inc. will post -4.74 EPS for the current year.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.